158 related articles for article (PubMed ID: 34295654)
21. T cell immunoglobulin and mucin-domain containing-3 in non-small cell lung cancer.
Jia K; He Y; Dziadziuszko R; Zhao S; Zhang X; Deng J; Wang H; Hirsch FR; Zhou C; Yu H; Zhang L
Transl Lung Cancer Res; 2019 Dec; 8(6):895-906. PubMed ID: 32010568
[TBL] [Abstract][Full Text] [Related]
22. Immune Microenvironment Differences Between Squamous and Non-squamous Non-small-cell Lung Cancer and Their Influence on the Prognosis.
Meng X; Gao Y; Yang L; Jing H; Teng F; Huang Z; Xing L
Clin Lung Cancer; 2019 Jan; 20(1):48-58. PubMed ID: 30341017
[TBL] [Abstract][Full Text] [Related]
23. Dynamic changes in PD-L1 expression and CD8
Choe EA; Cha YJ; Kim JH; Pyo KH; Hong MH; Park SY; Shim HS; Jung I; Lee CY; Cho BC; Kim HR
Lung Cancer; 2019 Oct; 136():30-36. PubMed ID: 31421259
[TBL] [Abstract][Full Text] [Related]
24. High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer.
Massarelli E; Lam VK; Parra ER; Rodriguez-Canales J; Behrens C; Diao L; Wang J; Blando J; Byers LA; Yanamandra N; Brett S; Morley P; Sharma P; Allison J; Wistuba II; Heymach JV
J Immunother Cancer; 2019 Dec; 7(1):351. PubMed ID: 31843013
[TBL] [Abstract][Full Text] [Related]
25. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
[TBL] [Abstract][Full Text] [Related]
26. Prognostic impact of the tumor immune microenvironment in pulmonary pleomorphic carcinoma.
Amemiya R; Miyoshi T; Aokage K; Suzuki J; Hoshino H; Udagawa H; Tane K; Sugano M; Kojima M; Fujii S; Kuwata T; Ochiai A; Goto K; Ikeda N; Tsuboi M; Ishii G
Lung Cancer; 2021 Mar; 153():56-65. PubMed ID: 33454518
[TBL] [Abstract][Full Text] [Related]
27. Identification and Validation of a Tumor Microenvironment-Related Gene Signature for Prognostic Prediction in Advanced-Stage Non-Small-Cell Lung Cancer.
Zhang X; Shi X; Zhao H; Jia X; Yang Y
Biomed Res Int; 2021; 2021():8864436. PubMed ID: 33860055
[TBL] [Abstract][Full Text] [Related]
28. Combination of PD-L1 expression and NLR as prognostic marker in patients with surgically resected non-small cell lung cancer.
Wang X; Cao L; Li S; Wang F; Huang D; Jiang R
J Cancer; 2019; 10(26):6703-6710. PubMed ID: 31777599
[No Abstract] [Full Text] [Related]
29. Comprehensive analyses of the heterogeneity and prognostic significance of tumor-infiltrating immune cells in non-small-cell lung cancer: Development and validation of an individualized prognostic model.
Pang Z; Chen X; Wang Y; Wang Y; Yan T; Wan J; Du J
Int Immunopharmacol; 2020 Sep; 86():106744. PubMed ID: 32623229
[TBL] [Abstract][Full Text] [Related]
30. Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma.
Giraldo NA; Becht E; Vano Y; Petitprez F; Lacroix L; Validire P; Sanchez-Salas R; Ingels A; Oudard S; Moatti A; Buttard B; Bourass S; Germain C; Cathelineau X; Fridman WH; Sautès-Fridman C
Clin Cancer Res; 2017 Aug; 23(15):4416-4428. PubMed ID: 28213366
[No Abstract] [Full Text] [Related]
31. Surprising impact of stromal TIL's on immunotherapy efficacy in a real-world lung cancer study.
Hashemi S; Fransen MF; Niemeijer A; Ben Taleb N; Houda I; Veltman J; Becker-Commissaris A; Daniels H; Crombag L; Radonic T; Jongeneel G; Tarasevych S; Looysen E; van Laren M; Tiemessen M; van Diepen V; Maassen-van den Brink K; Thunnissen E; Bahce I
Lung Cancer; 2021 Mar; 153():81-89. PubMed ID: 33465698
[TBL] [Abstract][Full Text] [Related]
32. Deciphering Microenvironment of NSCLC based on CD8+ TIL Density and PD-1/PD-L1 Expression.
Lin Z; Gu J; Cui X; Huang L; Li S; Feng J; Liu B; Zhou Y
J Cancer; 2019; 10(1):211-222. PubMed ID: 30662542
[No Abstract] [Full Text] [Related]
33. Multi-institutional TSA-amplified Multiplexed Immunofluorescence Reproducibility Evaluation (MITRE) Study.
Taube JM; Roman K; Engle EL; Wang C; Ballesteros-Merino C; Jensen SM; McGuire J; Jiang M; Coltharp C; Remeniuk B; Wistuba I; Locke D; Parra ER; Fox BA; Rimm DL; Hoyt C
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34266881
[TBL] [Abstract][Full Text] [Related]
34. Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8
Li YM; Yu JM; Liu ZY; Yang HJ; Tang J; Chen ZN
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31627272
[TBL] [Abstract][Full Text] [Related]
35. Prognostic impact of neutrophils-to-lymphocytes ratio (NLR), PD-L1 expression, and tumor immune microenvironment in laryngeal cancer.
Franz L; Alessandrini L; Fasanaro E; Gaudioso P; Carli A; Nicolai P; Marioni G
Ann Diagn Pathol; 2021 Feb; 50():151657. PubMed ID: 33189034
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical validation study of 15-gene biomarker panel predictive of benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of JBR.10.
Grieve S; Ding K; Moore J; Finniss M; Ray A; Lees M; Hossain F; Murugesan A; Agar J; Acar C; Taylor J; Shepherd FA; Reiman T
ESMO Open; 2020 Mar; 5(2):. PubMed ID: 32220948
[TBL] [Abstract][Full Text] [Related]
37. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients.
El-Guindy DM; Helal DS; Sabry NM; Abo El-Nasr M
J Egypt Natl Canc Inst; 2018 Dec; 30(4):125-131. PubMed ID: 30337185
[TBL] [Abstract][Full Text] [Related]
38. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
[TBL] [Abstract][Full Text] [Related]
39. Analysis of the prognostic role of an immune checkpoint score in resected non-small cell lung cancer patients.
Usó M; Jantus-Lewintre E; Calabuig-Fariñas S; Blasco A; García Del Olmo E; Guijarro R; Martorell M; Camps C; Sirera R
Oncoimmunology; 2017; 6(1):e1260214. PubMed ID: 28197383
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of tumor-infiltrating lymphocytes differs depending on histological type and smoking habit in completely resected non-small-cell lung cancer.
Kinoshita T; Muramatsu R; Fujita T; Nagumo H; Sakurai T; Noji S; Takahata E; Yaguchi T; Tsukamoto N; Kudo-Saito C; Hayashi Y; Kamiyama I; Ohtsuka T; Asamura H; Kawakami Y
Ann Oncol; 2016 Nov; 27(11):2117-2123. PubMed ID: 27502728
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
